IL320459A - RNA molecules encoding RSV-F and vaccines containing them - Google Patents
RNA molecules encoding RSV-F and vaccines containing themInfo
- Publication number
- IL320459A IL320459A IL320459A IL32045925A IL320459A IL 320459 A IL320459 A IL 320459A IL 320459 A IL320459 A IL 320459A IL 32045925 A IL32045925 A IL 32045925A IL 320459 A IL320459 A IL 320459A
- Authority
- IL
- Israel
- Prior art keywords
- rna molecule
- peg
- older
- age
- composition
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/317—Chemical structure of the backbone with an inverted bond, e.g. a cap structure
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/335—Modified T or U
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18541—Use of virus, viral particle or viral elements as a vector
- C12N2760/18543—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18571—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Plant Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Communicable Diseases (AREA)
- Optics & Photonics (AREA)
- Nanotechnology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Claims (36)
1. 2
2. CLAIMS1. An RNA molecule comprising at least one open reading frame encoding a respiratory syncytial virus (RSV) fusion protein F (F) polypeptide. 2. The RNA molecule of claim 1, wherein the RSV polypeptide is a full-length, truncated, fragment or variant thereof.
3. The RNA molecule of claim 1, wherein the RSV polypeptide comprises at least one mutation.
4. The RNA molecule of claim 1, wherein the RSV polypeptide has at least 90%, 95, 96%, 97%, 98% or 99% identity to the amino acid sequence selected from SEQ ID NO: 1 to 6 and 71 to 74.
5. The RNA molecule of claim 1, wherein the open reading frame is transcribed from a nucleic acid sequence having at least 90%, 95, 96%, 97%, 98%, or 99% identity to any one of the sequences of SEQ ID NOs: 7 to 10 and 59 to 62.
6. The RNA molecule of claim 1, wherein the open reading frame comprises a nucleic acid sequence having at least 90%, 95, 96%, 97%, 98%, or 99% identity to any one of the sequences of SEQ ID NOs: 11 to 16 and 63 to 70.
7. The RNA molecule of claim 1, wherein the open reading frame comprises a nucleic acid sequence of any one of SEQ ID NOs: 11 to 16 and 63 to 70.
8. The RNA molecule of claim 1, further comprising a 5’ untranslated region (5’ UTR).
9. The RNA molecule of claim 8, wherein the 5’ UTR comprises a sequence selected from any of SEQ ID NO: 17 to 19.
10. The RNA molecule of claim 1, further comprising a 3’ untranslated region (3’ UTR).
11. The RNA molecule of claim 10, wherein the 3’ UTR comprises the sequence of any one of SEQ ID NO: 20 to 25. 2
12. The RNA molecule of claim 1, wherein the RNA molecule further comprises a 5’ cap moiety or a 3’ poly-A tail.
13. The RNA molecule of claim 12, wherein the poly-A tail comprises a sequence having SEQ ID NO: 26.
14. The RNA molecule of claim 1, wherein the open reading frame comprises a G/C content of at least 55%, 60%, 65%, 70%, or 75%, or of or of about 50% to 75% or 55% to 70%.
15. The RNA molecule of claim 1, wherein the encoded RSV polypeptide localizes in the cellular membrane, localizes in the Golgi and/or is secreted.
16. The RNA molecule of claim 1, wherein the RNA comprises at least one modified nucleotide.
17. The RNA molecule of claim 16, wherein the modified nucleotide is pseudouridine, N1-methylpseudouridine, N1-ethylpseudouridine, 2-thiouridine, 4′-thiouridine, 5-methylcytosine, 5-methyluridine, 2-thio-1-methyl-1-deaza-pseudouridine, 2-thio-1-methyl-pseudouridine, 2-thio-5-aza-uridine, 2-thio-dihydropseudouridine, 2-thio-dihydrouridine, 2-thio-pseudouridine, 4-methoxy-2-thio-pseudouridine, 4-methoxy-pseudouridine, 4-thio-1-methyl-pseudouridine, 4-thio-pseudouridine, 5-aza-uridine, dihydropseudouridine, 5-methoxyuridine OR 2′-O-methyl uridine.
18. The RNA molecule of claim 17, wherein the modified nucleotide is N1-methylpseudouridine (Ψ).
19. The RNA molecule of claim 1, wherein the RNA is mRNA.
20. The RNA molecule of claim 19, wherein the RNA is modRNA or saRNA.
21. A composition comprising the RNA molecule of claim 1, wherein the RNA molecule is formulated in a lipid nanoparticle (LNP). 2
22. The composition of claim 21, wherein lipid nanoparticle comprises at least one of a cationic lipid, a PEGylated lipid, a neutral lipid, and a steroid or steroid analog.
23. The composition of claim 22, wherein the cationic lipid is (4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315).
24. The composition of claim 22, wherein the PEGylated lipid is PEG-modified phosphatidylethanolamine, PEG-modified phosphatidic acid, PEG-modified ceramides (e.g. PEG-CerC14 or PEG-CerC20), PEG-modified dialkylamines, PEG-modified diacylglycerols, PEG-modified dialkylglycerols, 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide, glycol-lipids including PEG-c-DOMG, PEG-c-DMA, PEG-s-DMG,N-[(methoxy polyethylene glycol)2000)carbamyl]-1,2-dimyristyloxlpropyl-3-amine (PEG-c-DMA), and PEG-2000-DMG, PEGylated diacylglycerol (PEG-DAG) such as 1 -(monomethoxy-polyethyleneglycol)-2,3-dimyristoylglycerol (PEG-DMG), a PEGylated phosphatidylethanoloamine (PEG-PE), a PEG succinate diacylglycerol (PEG-S-DAG) such as 4-O-(2’,3’- di(tetradecanoyloxy)propyl-1-O-((o-methoxy(polyethoxy)ethyl)butanedioate (PEG-S-DMG), a PEGylated ceramide (PEG-cer), or a PEG dialkoxypropylcarbamate such as co-methoxy(polyethoxy)ethyl-N-(2,3di(tetradecanoxy)propyl)carbamate or 2,3-di(tetradecanoxy)propyl-N-(u>- methoxy(polyethoxy)ethyl)carbamate.
25. The composition of claim 24, wherein the PEGylated lipid is 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159).
26. The composition of claim 22, wherein the neutral lipid is distearoylphosphatidylcholine (DSPC), dioleoylphosphatidylcholine (DOPC), dipalmitoylphosphatidylcholine (DPPC), dioleoylphosphatidylglycerol (DOPG), dipalmitoylphosphatidylglycerol (DPPG), dioleoyl-phosphatidylethanolamine (DOPE), palmitoyloleoylphosphatidylcholine (POPC), palmitoyloleoyl-phosphatidylethanolamine (POPE) and dioleoyl-phosphatidylethanolamine 4-(N-maleimidomethyl)-cyclohexane-1carboxylate (DOPE-mal), dipalmitoyl phosphatidyl ethanolamine (DPPE), dimyristoylphosphoethanolamine (DMPE), distearoyl- phosphatidylethanolamine (DSPE), 16-O-monomethyl PE, 16-O- 2 dimethyl PE, 18-1-trans PE, 1-stearioyl-2- oleoylphosphatidyethanol amine (SOPE), or 1,2-dielaidoyl-sn-glycero-3-phophoethanolamine (transDOPE).
27. The composition of claim 26, wherein the neutral lipid is 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC).
28. The composition of claim 22, wherein the steroid or steroid analog is cholesterol.
29. The RNA molecule of claim 1 for use in a method of inducing an immune response against RSV in a subject.
30. The RNA molecule of claim 1 for use in a method of preventing, treating or ameliorating an infection, disease or condition associated with RSV in a subject.
31. The RNA molecule for use of claim 30, wherein the infection, disease or condition is RSV infection-induced acute respiratory tract illness, including pneumonia and bronchitis.
32. The RNA molecule for use of claim 29 or 30, wherein the subject is less than about 1 year of age, about 1 year of age or older, about 5 years of age or older, about 10 years of age or older, about 20 years of age or older, about 30 years of age or older, about 40 years of age or older, about 50 years of age or older, about 60 years of age or older, about 70 years of age or older, or older.
33. The RNA molecule for use of claim 29 or 30, wherein the RNA molecule is administered as a vaccine.
34. The RNA molecule for use of claim 29 or 30, wherein the subject is administered a single dose, two doses, three doses, or more, and optionally, a booster dose of the RNA molecule.
35. The composition of claim 22 for use in a method of inducing an immune response against RSV in a subject. 2
36. The composition of claim 22 for use in a method of preventing, treating or ameliorating an infection, disease or condition associated with RSV in a subject.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263381238P | 2022-10-27 | 2022-10-27 | |
| US202363585254P | 2023-09-26 | 2023-09-26 | |
| PCT/IB2023/060798 WO2024089633A1 (en) | 2022-10-27 | 2023-10-26 | Rna molecules encoding rsv-f and vaccines containing them |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL320459A true IL320459A (en) | 2025-06-01 |
Family
ID=88690013
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL320459A IL320459A (en) | 2022-10-27 | 2023-10-26 | RNA molecules encoding RSV-F and vaccines containing them |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP4608440A1 (en) |
| JP (1) | JP2026512632A (en) |
| KR (1) | KR20250096808A (en) |
| CN (1) | CN120153078A (en) |
| AU (1) | AU2023369585A1 (en) |
| CO (1) | CO2025005088A2 (en) |
| IL (1) | IL320459A (en) |
| MX (1) | MX2025004821A (en) |
| PE (1) | PE20251592A1 (en) |
| TW (1) | TWI888970B (en) |
| WO (1) | WO2024089633A1 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4788369A2 (en) | 2023-10-06 | 2026-08-12 | Pfizer Inc. | Immunogenic compositions |
| WO2025186725A2 (en) | 2024-03-06 | 2025-09-12 | Pfizer Inc. | Improved lnp formulations and uses thereof |
| WO2026038177A1 (en) | 2024-08-16 | 2026-02-19 | Pfizer Inc. | Immunogenic compositions and uses thereof |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4367110A (en) | 1979-07-02 | 1983-01-04 | Toppan Printing Co. | Decorative laminate and a manufacturing method therefor |
| US4452901A (en) | 1980-03-20 | 1984-06-05 | Ciba-Geigy Corporation | Electrophoretically transferring electropherograms to nitrocellulose sheets for immuno-assays |
| US4596792A (en) | 1981-09-04 | 1986-06-24 | The Regents Of The University Of California | Safe vaccine for hepatitis containing polymerized serum albumin |
| JPS5938877A (en) | 1982-08-30 | 1984-03-02 | Musashi Eng Kk | Paper leaf discriminating method |
| US4599230A (en) | 1984-03-09 | 1986-07-08 | Scripps Clinic And Research Foundation | Synthetic hepatitis B virus vaccine including both T cell and B cell determinants |
| US4599231A (en) | 1984-03-09 | 1986-07-08 | Scripps Clinic And Research Foundation | Synthetic hepatitis B virus vaccine including both T cell and B cell determinants |
| US4608251A (en) | 1984-11-09 | 1986-08-26 | Pitman-Moore, Inc. | LHRH analogues useful in stimulating anti-LHRH antibodies and vaccines containing such analogues |
| US4601903A (en) | 1985-05-01 | 1986-07-22 | The United States Of America As Represented By The Department Of Health And Human Services | Vaccine against Neisseria meningitidis Group B serotype 2 invasive disease |
| AU769539B2 (en) | 1999-01-29 | 2004-01-29 | Zoetis Services Llc | Adjuvants for use in vaccines |
| DE60117164T2 (en) | 2000-11-07 | 2006-08-03 | Immuno Vaccine Technologies Inc., Halifax | VACCINES WITH INCREASED IMMUNE RESPONSE AND METHOD FOR THE PRODUCTION THEREOF |
| EP1519714B1 (en) | 2002-06-28 | 2010-10-20 | Protiva Biotherapeutics Inc. | Method and apparatus for producing liposomes |
| JP5639338B2 (en) | 2005-07-27 | 2014-12-10 | プロチバ バイオセラピューティクス インコーポレイティッド | Liposome production system and production method |
| EP1997830A1 (en) | 2007-06-01 | 2008-12-03 | AIMM Therapeutics B.V. | RSV specific binding molecules and means for producing them |
| SG10201408164XA (en) | 2007-12-11 | 2015-01-29 | Scripps Research Inst | Compositions and methods related to mrna translational enhancer elements |
| US8563002B2 (en) | 2007-12-24 | 2013-10-22 | Glaxosmithkline Biologicals, S.A. | Recombinant RSV antigens |
| PL2445526T3 (en) | 2009-06-24 | 2017-08-31 | Glaxosmithkline Biologicals S.A. | Recombinant rsv antigens |
| EP4183412B1 (en) | 2009-07-15 | 2024-08-14 | GlaxoSmithKline Biologicals SA | Rsv f protein compositions and methods for making same |
| WO2011043643A1 (en) | 2009-10-06 | 2011-04-14 | Medimmune Ltd | Rsv-specific binding molecule |
| WO2012019630A1 (en) | 2010-08-13 | 2012-02-16 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded protein |
| WO2013016058A1 (en) | 2011-07-22 | 2013-01-31 | Merck Sharp & Dohme Corp. | Novel bis-nitrogen containing cationic lipids for oligonucleotide delivery |
| WO2013078199A2 (en) | 2011-11-23 | 2013-05-30 | Children's Medical Center Corporation | Methods for enhanced in vivo delivery of synthetic, modified rnas |
| US20140308304A1 (en) | 2011-12-07 | 2014-10-16 | Alnylam Pharmaceuticals, Inc. | Lipids for the delivery of active agents |
| WO2013103659A1 (en) | 2012-01-04 | 2013-07-11 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Stabilizing rna by incorporating chain-terminating nucleosides at the 3'-terminus |
| ES2660129T3 (en) | 2012-03-27 | 2018-03-20 | Curevac Ag | Artificial nucleic acid molecules comprising a 5'UTR-TOP |
| EP4421177A3 (en) | 2013-03-13 | 2024-12-18 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Prefusion rsv f proteins and their use |
| PT2988780T (en) | 2013-04-25 | 2019-03-25 | Janssen Vaccines & Prevention Bv | Stabilized soluble prefusion rsv f polypeptides |
| CN105408348B (en) | 2013-06-17 | 2021-07-06 | 扬森疫苗与预防公司 | Stabilized soluble prefusion RSV F polypeptide |
| WO2015013551A1 (en) | 2013-07-25 | 2015-01-29 | Marshall Christopher Patrick | Conformationally stabilized rsv pre-fusion f proteins |
| EP2974739A1 (en) | 2014-07-15 | 2016-01-20 | Novartis AG | RSVF trimerization domains |
| CA2953341C (en) | 2014-06-25 | 2023-01-24 | Acuitas Therapeutics Inc. | Lipids and lipid nanoparticle formulations for delivery of nucleic acids |
| WO2016005004A1 (en) | 2014-07-11 | 2016-01-14 | Biontech Rna Pharmaceuticals Gmbh | Stabilization of poly(a) sequence encoding dna sequences |
| EP4023755B1 (en) | 2014-12-12 | 2023-04-26 | CureVac SE | Artificial nucleic acid molecules for improved protein expression |
| AU2016289496B2 (en) | 2015-07-07 | 2021-02-04 | Janssen Vaccines & Prevention B.V. | Stabilized soluble pre-fusion RSV F polypeptides |
| CN107847580B (en) | 2015-07-07 | 2022-08-12 | 扬森疫苗与预防公司 | Vaccines against RSV |
| US20180271970A1 (en) * | 2015-10-22 | 2018-09-27 | Modernatx, Inc. | Respiratory syncytial virus vaccine |
| CN108368028B (en) | 2015-10-28 | 2021-09-03 | 爱康泰生治疗公司 | Novel lipid and lipid nanoparticle formulations for delivery of nucleic acids |
| RU2723039C2 (en) | 2015-12-23 | 2020-06-08 | Пфайзер Инк. | Protein f rsv mutants |
| AU2017248018A1 (en) | 2016-04-05 | 2018-09-27 | Janssen Vaccines & Prevention B.V. | Vaccine against RSV |
| WO2018109220A2 (en) | 2016-12-16 | 2018-06-21 | Institute For Research In Biomedicine | Novel recombinant prefusion rsv f proteins and uses thereof |
| PL3908568T3 (en) | 2019-01-11 | 2024-12-02 | Acuitas Therapeutics, Inc. | Lipids for lipid nanoparticle delivery of active agents |
| KR20220133911A (en) * | 2020-01-30 | 2022-10-05 | 모더나티엑스, 인크. | Respiratory Virus Immunization Composition |
| WO2022032154A2 (en) | 2020-08-06 | 2022-02-10 | Modernatx, Inc. | Compositions for the delivery of payload molecules to airway epithelium |
| US20230355743A1 (en) | 2020-09-25 | 2023-11-09 | Modernatx, Inc. | Multi-proline-substituted coronavirus spike protein vaccines |
| US20240041785A1 (en) * | 2020-11-16 | 2024-02-08 | BioNTech SE | Compositions and methods for stabilization of lipid nanoparticle mrna vaccines |
-
2023
- 2023-10-26 CN CN202380075365.8A patent/CN120153078A/en active Pending
- 2023-10-26 AU AU2023369585A patent/AU2023369585A1/en active Pending
- 2023-10-26 PE PE2025000887A patent/PE20251592A1/en unknown
- 2023-10-26 WO PCT/IB2023/060798 patent/WO2024089633A1/en not_active Ceased
- 2023-10-26 IL IL320459A patent/IL320459A/en unknown
- 2023-10-26 EP EP23800587.0A patent/EP4608440A1/en active Pending
- 2023-10-26 TW TW112141022A patent/TWI888970B/en active
- 2023-10-26 JP JP2025523515A patent/JP2026512632A/en not_active Withdrawn
- 2023-10-26 KR KR1020257017392A patent/KR20250096808A/en not_active Withdrawn
-
2025
- 2025-04-23 CO CONC2025/0005088A patent/CO2025005088A2/en unknown
- 2025-04-24 MX MX2025004821A patent/MX2025004821A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN120153078A (en) | 2025-06-13 |
| AU2023369585A1 (en) | 2025-04-10 |
| CO2025005088A2 (en) | 2025-05-08 |
| WO2024089633A1 (en) | 2024-05-02 |
| KR20250096808A (en) | 2025-06-27 |
| MX2025004821A (en) | 2025-06-02 |
| TWI888970B (en) | 2025-07-01 |
| EP4608440A1 (en) | 2025-09-03 |
| PE20251592A1 (en) | 2025-06-16 |
| JP2026512632A (en) | 2026-04-20 |
| TW202424187A (en) | 2024-06-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250161434A1 (en) | Coronavirus vaccine compositions and methods | |
| US12509666B2 (en) | MRNA therapy for phenylketonuria | |
| US20250145577A1 (en) | Stereochemically enriched compositions for delivery of nucleic acids | |
| JP7774615B2 (en) | Lipid nanoparticle encapsulation of large RNA | |
| EP1648519B1 (en) | Lipid encapsulated interfering rna | |
| US12564645B2 (en) | Methods for treatment of methylmalonic acidemia | |
| US20230226147A1 (en) | Composition and methods for treatment of primary ciliary dyskinesia | |
| US10780183B2 (en) | Messenger RNA therapy for the treatment of Friedreich's ataxia | |
| US20240301007A1 (en) | Methods and compositions for quadrivalent influenza vaccine | |
| KR20250096808A (en) | RNA molecule encoding RSV-F and vaccine comprising the same | |
| RU2025110755A (en) | RNA MOLECULES ENCODING RSV-F AND VACCINES CONTAINING THEM | |
| RU2024110013A (en) | RNA MOLECULES | |
| RU2025135484A (en) | METHOD FOR RNA STABILIZATION | |
| RU2024116295A (en) | POLYNUCLEOTIDE COMPOSITIONS AND THEIR APPLICATIONS | |
| WO2026029847A1 (en) | Methods and compositions for pandemic influenza vaccine | |
| WO2024057237A1 (en) | Lipid nanoparticles | |
| WO2026033123A1 (en) | Lipid nanoparticle formulations for mrna delivery |